#Counterfeit
Grey-market supply, identity testing, vendor accountability stories.
How chemists test what's in GLP-1 drugs
A new peer-reviewed method identifies nine GLP-1 drugs at once. Here is why that kind of identity testing matters right now.
What Lilly's retatrutide lawsuits mean
Eli Lilly sued six US sellers of unapproved retatrutide on 12 August 2026. Here is what the cases mean if you bought a vial or are considering one.
BPC-157 Grey Market Risks and Quality
BPC-157 is sold online with no regulatory oversight. What COA testing can and cannot tell you about identity, purity, and contamination.
PT-141 Grey Market Risks and Quality
Grey-market PT-141 vials lack the controls of FDA-approved Vyleesi. What COA testing reveals about identity, purity, and contamination.
Retatrutide grey market risks
Retatrutide is unapproved and ineligible for compounding. Grey-market vials carry identity, purity, and contamination risks.
Semaglutide Grey Market Risks and Quality
Counterfeit Ozempic, compounded semaglutide salt forms, and dosing errors: what regulators have found and what a COA cannot tell you.
Semax Grey Market Risks and Quality Testing
Semax is sold online with no regulatory oversight outside Russia. What COA testing reveals about identity, purity, and contamination.
Tesamorelin Grey Market Risks and Quality
Tesamorelin is FDA-approved only for HIV lipodystrophy. Grey-market vials sold for off-label use carry identity, purity, and contamination risks.
Tirzepatide Grey Market Risks and Quality
Counterfeit Mounjaro pens, compounded tirzepatide after the shortage ended, and FDA recalls: what regulators have found and what a COA cannot tell you.